Marrow Launches With 173 Million for Marrow Delivery

Company Marrow Therapeutics Event Type Launch with Series A and Series B financing ($173 million combined) Modality TfR1-targeted antibody bioconjugate for in vivo genetic payload delivery Asset MAR-101; TAB platform Target TfR1 (delivery); BCL11A (payload) Disease Area Sickle cell disease; beta thalassemia Summary Marrow Therapeutics…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *